Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
WuXi Biologics (Cayman) Inc.의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
WuXi Biologics (Cayman) Inc. 주요 수익원은 Biologics이며, 최신 수익 발표에서 수익은 15,972,158,570입니다. 지역별로는 North America이 WuXi Biologics (Cayman) Inc.의 주요 시장이며, 수익은 11,596,649,464입니다.
WuXi Biologics (Cayman) Inc.은 수익성이 있나요?
예, 최신 재무제표에 따르면 WuXi Biologics (Cayman) Inc.의 순이익은 $3,356입니다.
WuXi Biologics (Cayman) Inc.에 부채가 있나요?
예, WuXi Biologics (Cayman) Inc.의 부채는 15,158입니다.
WuXi Biologics (Cayman) Inc.의 발행 주식은 몇 주인가요?
WuXi Biologics (Cayman) Inc.의 총 발행 주식은 4,105.93주입니다.